Inventiva S.A. (IVA)Healthcare | Biotechnology | Daix, France | NasdaqGM
4.71 USD
-0.20
(-3.980%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 4.71 |
Hot Take ↕ | Aug. 22, 2026, 4:40 a.m. EDT
The investment case here is a stark dichotomy between a speculative catalyst play and a fundamentally broken business. On the surface, the analyst consensus is aggressively bullish, with a mean target price of nearly $15, implying a massive upside from current levels. However, the underlying reality is dire: the company is hemorrhaging cash with negative free cash flow of over $200 million, operating margins in the negative 60s, and revenue that has collapsed by nearly 90% year-over-year. The balance sheet is precarious, with debt significantly exceeding cash reserves, forcing the company to constantly revise its cash runway and issue warrants just to survive. While the options market is screaming for a turnaround—betting on a specific event that could revive the stock—the fundamental trajectory shows no sign of recovery. The stock has lost more than half its value over the last five years, and the most recent annual data point still reflects a period of severe contraction. There is no sustainable revenue growth, no profitability, and no fortress balance sheet to support a 'buy and hold' thesis. The recent price bounce appears to be a technical relief rally rather than a reversal of the long-term downtrend. For investors, this is a high-risk lottery ticket dependent entirely on a future commercialization success, not a sound investment in a viable company. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.080846 |
| MSTL | 0.097903 |
| AutoETS | 0.098122 |
| AutoARIMA | 0.098122 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 0.42 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.102 |
| Excess Kurtosis | -1.19 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.036 |
| Market Cap | 1,111,418,112 |
| Forward P/E | -5.65 |
| Beta | 0.91 |
| Website | https://inventivapharma.com |
As of Aug. 22, 2026, 4:40 a.m. EDT: Speculators are positioning for a significant upside move, evidenced by massive open interest in out-of-the-money January 2027 calls at the $10 strike (over 20,000 contracts), which is more than double the volume of the nearest expiration. This heavy positioning suggests a belief in a potential commercialization event or partnership announcement that could drive the price toward the $10 level within the next year. Conversely, put activity is negligible, indicating a lack of hedging against downside risk despite the stock's recent volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.105513334 |
| Address1 | 50 rue de Dijon |
| All Time High | 19.064 |
| All Time Low | 1.53 |
| Ask | 4.45 |
| Ask Size | 4 |
| Average Daily Volume10 Day | 683,870 |
| Average Daily Volume3 Month | 1,081,701 |
| Average Volume | 1,081,701 |
| Average Volume10Days | 683,870 |
| Beta | 0.913 |
| Bid | 4.55 |
| Bid Size | 1 |
| Book Value | -0.17277963 |
| City | Daix |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.705 |
| Current Ratio | 3.159 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 4.83 |
| Day Low | 4.62 |
| Display Name | Inventiva |
| Earnings Call Timestamp End | 1,774,987,200 |
| Earnings Call Timestamp Start | 1,774,987,200 |
| Earnings Timestamp | 1,790,366,400 |
| Earnings Timestamp End | 1,790,366,400 |
| Earnings Timestamp Start | 1,790,366,400 |
| Ebitda | -132,497,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -8.365 |
| Enterprise To Revenue | 163.928 |
| Enterprise Value | 1,108,314,624 |
| Eps Current Year | -0.80367 |
| Eps Forward | -0.83283 |
| Eps Trailing Twelve Months | -2.21 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 4.3774 |
| Fifty Day Average Change | 0.3276 |
| Fifty Day Average Change Percent | 0.074838944 |
| Fifty Two Week Change Percent | -10.551333 |
| Fifty Two Week High | 7.983 |
| Fifty Two Week High Change | -3.2779999 |
| Fifty Two Week High Change Percent | -0.41062257 |
| Fifty Two Week Low | 3.35 |
| Fifty Two Week Low Change | 1.355 |
| Fifty Two Week Low Change Percent | 0.40447763 |
| Fifty Two Week Range | 3.35 - 7.983 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,594,387,800,000 |
| Float Shares | 157,915,839 |
| Forward Eps | -0.83283 |
| Forward P E | -5.649412 |
| Free Cashflow | -200,711,632 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 69 |
| Fullday Change | -0.195 |
| Fullday Change Percent | -3.9796 |
| Fullday Price | 4.705 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.99675006 |
| Gross Profits | 6,739,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.41803002 |
| Implied Shares Outstanding | 236,220,651 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-07-10 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. |
| Long Name | Inventiva S.A. |
| Market | us_market |
| Market Cap | 1,111,418,112 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_273516426 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -354,137,984 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,168,722,903 |
| Number Of Analyst Opinions | 13 |
| Open | 4.83 |
| Operating Cashflow | -104,884,000 |
| Operating Margins | -67.10686 |
| Payout Ratio | 0.0 |
| Phone | 33 3 80 44 75 00 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 4.705 |
| Post Market Time | 1,787,947,804 |
| Previous Close | 4.9 |
| Price Eps Current Year | -5.854393 |
| Price Hint | 4 |
| Price To Book | -27.231218 |
| Price To Sales Trailing12 Months | 164.38664 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.408 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.195 |
| Regular Market Change Percent | -3.9796 |
| Regular Market Day High | 4.83 |
| Regular Market Day Low | 4.62 |
| Regular Market Day Range | 4.62 - 4.83 |
| Regular Market Open | 4.83 |
| Regular Market Previous Close | 4.9 |
| Regular Market Price | 4.705 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,124,657 |
| Return On Assets | -0.45079 |
| Revenue Growth | -0.899 |
| Revenue Per Share | 0.036 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 236,220,651 |
| Shares Percent Shares Out | 0.0109 |
| Shares Short | 2,580,307 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,787,962 |
| Short Name | Inventiva S.A. - American Depos |
| Short Percent Of Float | 0.0116 |
| Short Ratio | 3.38 |
| Source Interval | 15 |
| Symbol | IVA |
| Target High Price | 26.0 |
| Target Low Price | 8.8 |
| Target Mean Price | 14.88369 |
| Target Median Price | 13.0 |
| Total Cash | 99,839,000 |
| Total Cash Per Share | 0.481 |
| Total Debt | 230,890,000 |
| Total Revenue | 6,761,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.05115 |
| Two Hundred Day Average Change | -0.34614992 |
| Two Hundred Day Average Change Percent | -0.068528935 |
| Type Disp | Equity |
| Volume | 1,124,657 |
| Website | https://inventivapharma.com |
| Zip | 21,121 |